Compare Expeditors International of Wshngtn Inc (EXPD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs BIO-TECHNE Corp — how do they compare? Expeditors International of Wshngtn Inc trades at $191.67 (market cap $25.18B), while BIO-TECHNE Corp trades at $72.45 (market cap $11.36B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 2.2× BIO-TECHNE Corp's market cap, and Expeditors International of Wshngtn Inc pays the higher dividend (0.84%). Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and BIO-TECHNE Corp for 63 Days on average.
| EXPD | TECH | |
|---|---|---|
Market Cap | $25.18B | $11.36B |
Volume | 1,003,557 | 5,390,331 |
Sector | Industrials | Health |
52-Week High | $194.12 | $72.61 |
52-Week Low | $113.13 | $43.31 |
Typical Hold Time | 43 Days | 63 Days |
Enterprise Value | $24.72B | $11.39B |
Dividend Yield | 0.84% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expeditors International (EXPD) trades at $193.52, up 1.4% on the day, with a bullish technical signal from moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $2.20. Revenue grew to $11.07B in 2025, while net income held steady at $810M. The company maintains strong profitability with a 42.6% ROE, though valuation multiples like the 28.2 P/E are elevated relative to historical norms.
Outlook is mixed; efficiency initiatives and airfreight demand support growth, but analyst consensus is cautious with a $179.43 price target below the current price. Key risks include reliance on global trade cycles and potential margin pressure. Upside depends on continued earnings beats and sustained freight market strength.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
